Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. - Test2 - elhamkhani - TriplyDB

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

http://www.wikidata.org/entity/Q27851896

about

PC-9/GR4 PC-9/WZR09 PC-9/WZR10 PC-9/WZR11 PC-9/WZR12

P1343

ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC Predictive biomarkers in precision medicine and drug development against lung cancer Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer Targeted therapies in development for non-small cell lung cancer Signaling cross-talk in the resistance to HER family receptor targeted therapy CIViC database Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions.Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.EGFR: The Paradigm of an Oncogene-Driven Lung Cancer Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation.EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer Mechanisms of resistance to EGFR targeted therapies.Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.

P2860

Q54938497-5670E224-72E0-4709-A813-D341CD86E1C1 Q54938505-CE5381BD-DA19-4558-80EE-0ECE8405AC6B Q54938506-0CDEFF01-9360-4B37-A18A-EB74D30897A3 Q54938507-44905F90-DB2C-4A81-8F11-D4B08B0AD1AF Q54938508-2BE487EF-E66B-4D03-B7F2-F9A5C748510C

P1343

Q26744787-830BACEA-D527-422E-9773-FE049D036B4F Q26747276-80413C94-4AAF-40CD-8B70-0CA51A569319 Q26824536-714C6BB1-C9F4-4B3F-AA68-D12CCEDCA217 Q26865779-2D9B5D79-EA18-45CF-A1A8-498D24FED04F Q27022852-87144895-0F4C-411E-9543-40AA36D55338 Q27027778-74E21352-E1E8-4A23-8954-73920327A2E3 Q27612411-7B2807BA-8842-41BA-95EA-06C2008DEB74 Q27852116-4AD4624E-CAFA-40DB-871F-2D52334B1457 Q27852553-201007F6-5656-407D-9C30-353E7E6551AF Q27853013-FB820B86-E841-462C-B08D-7C149B93DFB4 Q27853189-954C8560-52B9-460F-B10F-E0171EB61BF6 Q27853317-DA13081B-05C7-4CDC-AA5C-1941D0E3168E Q28067196-D9F7374B-B13E-40EC-B420-46A170919A09 Q28259999-9C5AF3A7-05A8-48E4-A2D3-11D55BB48399 Q31053925-41C427C0-45E0-414F-92B2-E770D44B4E7B Q33572728-A5E5997B-1FC0-4FF8-9D28-6A0633383E7F Q33601653-F8DFA531-1A67-46A3-B0BA-2CAE6DC2D6A9 Q33719411-89218ADB-BED9-4234-9503-4DA6F82550B9 Q33726782-B8C1E15C-31EC-449B-A61D-4C62470C4242 Q34260686-AEA36120-1BC7-4BA4-9DFA-3DD5024F2973 Q34392733-2D3D8601-5BAB-40A5-92E8-DD97EB31CC2F Q34550460-DD5B6955-9B11-44BE-99BC-820614B33F86 Q34686900-477BDA6D-9C86-49B4-B696-B359142AD885 Q35112467-82C41338-C62C-4B85-987C-DD36D565D2D6 Q35337927-05584A72-31E1-48E2-B5CB-433D1BC2C9BC Q35619241-9A5FB635-B8B7-4D53-9932-2323F39CAF41 Q35994416-1BF950B0-93B6-4A1E-BD94-052CA0586FAF Q36036046-9E2810AF-8149-497A-A350-1E9324E7762A Q36104980-7241FCE3-41E5-4E6C-93EB-7010F554EFB5 Q36427381-171B1AFE-96A3-4080-A355-E310CC4807D1 Q36525647-1B148B27-CFAE-45BE-AA12-23648F32DE25 Q36560547-0DE82485-77C1-4C52-92BB-F8D8AC2C32D8 Q36605057-D3E13B9C-5F81-4F35-8880-29FD59807EAC Q36660669-44750487-3CF2-4769-9CC1-510835429FBF Q36673653-1FA05521-2FD3-44F7-AECE-95AD44120F0E Q36687288-E9F95B6D-5A62-4EFE-9D84-95818F4A4F01 Q36775204-863BF9AE-7254-4DBF-9F08-670D3974B292 Q36801144-DDF65F3B-BC9C-4512-ABD7-ED57F197DDF6 Q36887721-3D73A3F3-B4DA-4B58-8EA2-A6473037469F Q36970403-942B3463-9899-4C36-80EB-14431BBCC968

P2860

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

http://www.wikidata.org/entity/Q27851896

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

@ast

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

@en

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

@nl

type

label

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

@ast

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

@en

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

@nl

altLabel

Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors

@en

prefLabel

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

@ast

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

@en

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

@nl

P1433

Q27851896-98213DDD-D627-4054-BF1A-EC68CA7F72E4

P1476

Q27851896-B9CA0986-A165-4A39-9E52-5DB90EF8EE8C

P2093

Q27851896-0F4DD737-AD24-4219-A3C0-5192F6CA5E07

Q27851896-11CC550C-9F1C-4742-B7D7-BE3165852628

Q27851896-18D7C779-C5BC-43C9-A905-D345472CC5D3

Q27851896-19542A84-DDBF-474F-A990-6A7D5A18D1E8

Q27851896-19BFDE4D-B82E-4922-82E5-8D21A0B37A51

Q27851896-21CFD801-4119-44DC-9957-9DA726DA35E8

Q27851896-25006DF6-A8BA-45AC-BB08-D8B4B6A36730

Q27851896-2A5A9041-90B3-4B63-8346-3DB4109CA80D

Q27851896-3926BFF1-176A-4241-A102-B828F6196ACA

Q27851896-3A21B43E-8035-4209-97E8-2548563A5276

P2860

Q27851896-0082F388-2C7D-4E4F-BCC4-D4BEB2E90865

Q27851896-00840F31-9CC7-4AE0-9A10-5218663EF420

Q27851896-02BDF6C3-13DD-428E-BCB9-D9AFCE4E6F54

Q27851896-08FD8A9E-C137-4D98-8848-B9AB3DCF900E

Q27851896-0D09E564-A0CB-47A7-A2A0-3A9E35A2778E

Q27851896-1990FFF5-B770-4C34-A664-350AB3ED505C

Q27851896-1A2AB716-72AE-480B-951D-62303623BDC4

Q27851896-22C4848D-3680-48A9-9C0B-22C15E1965D3

Q27851896-290C9578-EBEE-4C74-A6B4-18799B83479A

Q27851896-442E2118-093A-4056-BDD4-E6D532FB8FB8

P304

Q27851896-E65F2CEE-0C7A-4E7B-8281-ABD94E6A3AAB

P31

Q27851896-2E51F032-E5A1-4F60-B7FF-0C842C25DF24

P3181

Q27851896-DED5CEFA-361E-4FF5-8251-DCF382BE9FE1

P356

Q27851896-85C9847B-70D3-4837-9BA8-56C2A5A8E68F

P433

Q27851896-0A1064C6-4421-432A-B41A-A8175094FBE7

P4510

Q27851896-04AAB220-BFFC-4B11-AC79-18132F1CC477

Q27851896-1FFCC4AD-59B9-42D8-B8FB-465497994232

Q27851896-3568E5C3-1A3D-46CD-9475-178614A78FAF

Q27851896-8DEE77E6-14B2-4EDF-B77B-2905DBB414E0

Q27851896-A6013690-F082-4A2B-9BD4-01FF7F99AEC5

P478

Q27851896-5A5D3BC1-3C6B-48E0-82EA-6606474752CC

P50

Q27851896-0DC272AF-D83F-4192-8FCB-B3433837BA92

Q27851896-16B73F49-93EB-4C7E-9C8E-78B21FEB3F3E

Q27851896-705CB3E8-473C-42E1-A7BF-9AC9C1BE9020

Q27851896-BA9B6529-1EB3-4CB4-8601-451608045C8F

Q27851896-DD3A7CB1-1B26-486D-B39F-9592EA900FA9

P577

Q27851896-AD8422BF-7325-469F-9336-167FF2EF215D

P5875

Q27851896-AB021276-B66D-43D3-AEF4-8AC6F4FAA38A

P698

Q27851896-97CAE826-16CF-4090-8882-1B8C67B0C66A

P921

Q27851896-7612B682-94A6-4B9E-8E13-08856811EB30

P932

Q27851896-CF771896-028E-430A-807F-47C081601F21

P3181

P356

2159-8290.CD-12-0103

P1433

Cancer Discovery

P1476

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors

@en

P2093

Andrew Rogers

http://www.w3.org/2001/XMLSchema#string

Anthony Letai

http://www.w3.org/2001/XMLSchema#string

Calixte S Monast

http://www.w3.org/2001/XMLSchema#string

Christine A Pratilas

http://www.w3.org/2001/XMLSchema#string

Chunxiao Xu

http://www.w3.org/2001/XMLSchema#string

Claire Repellin

http://www.w3.org/2001/XMLSchema#string

Dalia Ercan

http://www.w3.org/2001/XMLSchema#string

Elena V Ivanova

http://www.w3.org/2001/XMLSchema#string

Eva M Goetz

http://www.w3.org/2001/XMLSchema#string

Lynette Sholl

http://www.w3.org/2001/XMLSchema#string

P2860

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

P304

934-947

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

952909

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/2159-8290.CD-12-0103

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P4510

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Marzia Capelletti

Levi A Garraway

P577

2012-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230826400

http://www.w3.org/2001/XMLSchema#string

P698

22961667

http://www.w3.org/2001/XMLSchema#string

P921

P932

3477553

http://www.w3.org/2001/XMLSchema#string